ERYTECH submits EMA Marketing Authorization Application for GRASPA to treat acute lymphoblastic leukemia

ERYTECH announces today the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for eryaspase (Invented Name: GRASPA®) for the treatment of patients with acute lymphoblastic leukemia (ALL).

Menu